Mar 26, 2024 8:30am EDT Vivani Medical Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
Mar 01, 2024 7:49am EST Vivani Medical Announces Pricing of $15.0 Million Registered Direct Offering of Common Stock and Warrants
Feb 28, 2024 8:30am EST Vivani Medical Announces Positive NPM-115 Preclinical Weight Loss Data Comparable to Ozempic®/Wegovy® and Discloses NPM-139 as Semaglutide as Strategy Shifts to Prioritize Obesity Portfolio
Nov 14, 2023 6:00am EST Vivani Medical Provides Business Update and Reports Third Quarter Financial Results
Sep 05, 2023 6:00am EDT Vivani Medical Subsidiary Cortigent to Present Orion Clinical Study Results at The Eye and The Chip World Research Congress on Artificial Vision October 8-10
Aug 14, 2023 5:45pm EDT Vivani Medical Reports Second Quarter Financial Results and Provides Business Update